GOTHENBURG, Sweden, November 16, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the appointment of Robert Marchesani as an advisor to its board of directors. Mr. Marchesani has nearly 30 years of experience in the life science industry, leading a variety of business activities including product development, global branding and marketing with a particular focus on oncology.
Mr. Marchesani commented, “I am delighted to be joining Isofol’s team of advisors as it prepares for the initiation of its global Phase 3 clinical study of arfolitixorin. I look forward to working together with the board and executive team to achieve the company’s business and drug development goals and to work to improve outcomes for cancer patients.”
Dr. Jarl Ulf Jungnelius MD, Chairman of the Board of Isofol, added, “Mr. Marchesani brings a unique combination of global strategy, branding and marketing experience in the field of oncology. We believe Isofol will greatly benefit from his expertise as we continue to develop our drug candidate, arfolitixorin, which is entering a global Phase 3 clinical study in metastatic colorectal cancer.”
Mr. Marchesani is currently principal at Proventus Health Solutions, LLC and an adjunct faculty member and executive career mentor at Butler University, Lacy School of Business in Indianapolis, Indiana. At Proventus, he serves as a consultant to oncology companies to incorporate prescriber, patient and payer insights throughout drug development and commercialization. Prior to joining Proventus, Mr. Marchesani spent more than 25 years at Eli Lilly and Company where he led the global branding, marketing and launch of a number of cancer therapeutics including, ALIMTA® (pemetrexed), Gemzar® (gemcitabine) and Verzenio™ (abemaciclib). Mr. Marchesani received his Bachelor of Arts degree in journalism and public relations from Indiana University of Pennsylvania and Masters of Business Administration with a concentration in marketing from the University of Indianapolis.
For additional information, please contact:
Isofol Medical AB (publ):
Anders Rabbe, CEO
Phone: +46 (0)707 646 500
Phone: +41 79 598 7149
LifeSci Public Relations
Phone: +1 646-876-4932
Arfolitixorin is a new drug candidate developed to increase the efficacy of the cytotoxic agent 5‑fluorouracil (5-FU) and as a rescue drug after high-dose methotrexate treatment. Arfolitixorin, [6R]-5,10-methylene-tetrahydrofolate is the key active metabolite of the widely used folate-based drugs leucovorin and levoleucovorin. Arfolitixorin may be suitable for all patients regardless of their ability to activate folates to [6R]-5,10-methylenetetrahydrofolate, since arfolitixorin, unlike leucovorin and levoleucovorin, does not require metabolic activation to exert its effect.
About Isofol Medical AB (publ)
Isofol Medical AB (publ) is a biotech company within the field of oncology developing arfolitixorin, primarily as a treatment for advanced colorectal cancer and as a rescue drug after high-dose methotrexate treatment in osteosarcoma (bone cancer). Through a worldwide exclusive license agreement, Isofol holds the rights to develop and commercialise arfolitixorin within oncology with access to the unique patented production process and the production capabilities of Merck KGaA, Darmstadt, Germany. Isofol Medical AB is traded on the Nasdaq First North Premier. Certified Adviser is FNCA Sweden AB.
For further information, please contact